Quinolone pharmacokinetics and metabolism.
The pharmacokinetic properties of the new fluoroquinolones are characterized by a high volume of distribution, long biological half-life, low serum protein binding, elimination by renal and extrarenal mechanisms with high total and renal clearances, limited biotransformation and moderate to excellent bioavailability after oral administration. However, each quinolone derivative (ciprofloxacin, enoxacin, fleroxacin, norfloxacin, ofloxacin and pefloxacin) possesses individual pharmacokinetic parameters, which should be considered in the treatment of patients, especially when liver or renal dysfunction exists.
Lode
H
H
Medical Department of Klinikum Steglitz, Freie Universität Berlin, FRG.
Höffken
G
G
Boeckk
M
M
Deppermann
N
N
Borner
K
K
Koeppe
P
P
D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D001711:Biotransformation; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D015365:Enoxacin / Q000008:administration & dosage / Q000493:pharmacokinetics; D016576:Fleroxacin; D006207:Half-Life; D006801:Humans; D008657:Metabolic Clearance Rate; D009643:Norfloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics; D015242:Ofloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics; D015366:Pefloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics
D000890:Anti-Infective Agents; D015366:Pefloxacin; D015365:Enoxacin; D002939:Ciprofloxacin; D015242:Ofloxacin; D009643:Norfloxacin; D016576:Fleroxacin